Drug news
CHMP recommends Nimenrix vaccine (GSK) for Meningococcal Diseases
The CHMP has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Nimenrix, powder and solvent for solution for injection from GSK, intended for active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135 and Y.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.